drugset / Trial / NCT05117931
A Study of Amivantamab in People With Esophagogastric Cancer
Phase 2
Active not recruiting
25 enrolled
Memorial Sloan Kettering Cancer Center
Janssen Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see whether the study drug, amivantamab, is an effective treatment for people with EGFR- or MET-amplified esophagogastric cancer. The researchers will also look at whether amivantamab is a safe treatment that causes few or mild side effects in participants.
Timeline
- Start
- 2021-12-02
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amivantamab | Monoclonal antibody | 1050 mg | Intravenous |
| Subject | Amivantamab | Monoclonal antibody | 1400 mg | Intravenous |